Ziopharm Oncology to Exhibit at BIO Investor Forum 2010, Oct 5 - 6, 2010

NEW YORK--(BUSINESS WIRE)-- Press Kit Materials are Available at: http://www.tradeshownews.com/events/BIO-Investor-Forum-2010/ziopharm/

Company:

    Ziopharm Oncology
Event: BIO Investor Forum 2010
Oct 5 - 6, 2010
San Francisco, CA, US
Web:

http://www.ziopharm.com

About Ziopharm Oncology

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of cancer drugs. Our principal focus is on the development of proprietary small molecule drug candidates that work on validated targets. The goal is to develop intravenous ("IV") and/or oral forms of administration. We believe this strategy will result in lower-risk and lower-cost development programs with product candidates having a low cost of manufacturing to address changing reimbursement requirements around the world.



CONTACT:

Ziopharm Oncology
Lori Ann Cafarella, 646-214-0702
[email protected]
or
Ziopharm Oncology
Cathy Brown, 617-259-1970
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Clinical Trials  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.